CEO Executive AssistantResearch as a Strategic Imperative for Healthcare CEOs
Academic medical centers, integrated health systems, and specialty care organizations with research programs face a leadership challenge that most industries do not encounter: the work being delegated can directly affect patient safety and, in the case of clinical trials, the lives of research participants who have consented to uncertainty in the hope of advancing medicine.
This is not a function where the stakes of poor delegation can be measured only in financial or reputational terms. A research governance failure can harm patients. An inadequately supervised clinical trial can expose participants to preventable adverse events. A compliance breakdown in research integrity can result in federal debarment that ends an institution’s research program entirely.
For healthcare CEOs, delegating research and clinical trials means building a delegation architecture that is both efficient enough to support a high-volume research enterprise and rigorous enough to protect the humans who make that research possible.
Clarifying the CEO’s Role in Research Governance
Most healthcare CEOs are not scientists. You may have a clinical background, an administrative background, or a finance and operations background. Regardless, your role in research governance is not to evaluate scientific protocols or supervise clinical trials directly. It is to ensure that the governance systems, the people, and the culture that protect research integrity are in place and functioning.
This distinction matters because it defines what you should be holding leaders accountable for. You are not accountable for whether a Phase II trial meets its enrollment targets. You are accountable for whether the clinical research infrastructure has the oversight systems, the regulatory compliance posture, and the leadership capability to conduct trials safely and ethically.
Your direct research responsibilities as CEO typically include:
- Approving the institutional research strategy and investment priorities
- Ensuring adequate resources for research compliance and oversight infrastructure
- Holding the VP of Research (or equivalent) accountable for research enterprise performance
- Engaging with major research funders, including NIH, philanthropic foundations, and industry partners, at a relationship level
- Ensuring that your board is adequately informed about research enterprise performance and risks
- Setting the ethical tone that governs how your institution approaches research with human subjects
Everything else is delegated.
Building the Research Leadership Structure
The structural foundation of effective research delegation is having the right leadership in the right roles with clear, non-overlapping accountabilities.
Your VP of Research or Chief Research Officer owns the scientific and strategic direction of the research enterprise. They are responsible for the quality of the research portfolio, the development of research investigators, the external reputation of the institution’s research programs, and the cultivation of major research partnerships and funding relationships.
Your Research Compliance Officer or Institutional Research Compliance Program Director owns the regulatory and ethical oversight infrastructure. This includes maintaining your Institutional Review Board (IRB), ensuring compliance with federal research regulations (45 CFR Part 46, Good Clinical Practice guidelines, and OHRP oversight requirements), and managing research compliance audits and investigations.
Your Clinical Trials Office Director or equivalent owns the operational execution of clinical trials: protocol management, regulatory submissions, patient enrollment, data management, adverse event reporting, and sponsor relationship management.
These three roles need to work in close coordination but with genuinely separate accountabilities. Research compliance is most effective when it is independent from research operations. A compliance officer who reports to the person they are supposed to be overseeing has a structural conflict that undermines the integrity of the oversight function.
Delegating IRB Oversight
Your Institutional Review Board is the cornerstone of human subjects protection in your research enterprise. The IRB operates with regulatory authority derived from federal law and from your institution’s Federalwide Assurance (FWA) with the Office for Human Research Protections.
As CEO, you do not manage or direct the IRB. That independence is the point. Your IRB Chair and committee members make scientific and ethical determinations about research protocols independent of management pressure, including pressure from investigators who are generating revenue for the institution.
Your delegation responsibilities regarding the IRB are structural: ensure the IRB is adequately staffed and resourced, ensure IRB members receive appropriate training, and ensure that when the IRB identifies concerns or requires protocol modifications, the institutional response takes them seriously.
The most damaging thing a healthcare CEO can do to their IRB is create institutional pressure, direct or indirect, to expedite IRB review for commercially important studies or studies led by high-revenue physicians. This pressure, even when subtly applied, undermines the independence that makes your IRB a credible protector of research participants.
Build a firewall between research commercial interests and IRB decision-making, and maintain it even when the commercial pressures are significant.
For how clinical research governance connects to your broader clinical quality oversight model, the healthcare clinical delegation article provides a framework for integrating research quality with clinical quality governance.
Managing NIH and Federal Research Funding
Federal research funding from NIH, AHRQ, the Department of Defense, and other agencies represents a significant portion of the research revenue at most academic medical centers. Managing these relationships appropriately requires a specific delegation model.
Your VP of Research owns the strategic relationship with NIH program officers, agency leadership, and funding councils. This is a relationship-level activity that requires scientific credibility, institutional standing, and sustained personal engagement.
Your Sponsored Programs Office or equivalent owns the administrative management of federal grants: proposal submission, compliance with federal grant terms, financial reporting, and closeout. This administrative function is entirely delegable and should operate without CEO involvement in routine transactions.
Your involvement with federal funding should be limited to: strategic relationship meetings with NIH Institute Directors or equivalent, major grant applications that require a CEO commitment letter or institutional guarantee, and situations where your institution’s federal research standing is at risk due to a compliance finding or debarment proceeding.
The distinction between strategic relationship ownership (VP of Research) and administrative compliance ownership (Sponsored Programs Office) is critical. When these are confused, either the VP of Research gets pulled into compliance administration that consumes their strategic capacity, or the Sponsored Programs Office tries to make strategic decisions it is not positioned to make.
Industry-Sponsored Clinical Trials
Industry-sponsored trials represent a growing share of clinical research activity at health systems and academic medical centers. Pharmaceutical companies, device manufacturers, and biotechnology firms conduct trials at your institution because you have the patient populations, the investigator expertise, and the clinical infrastructure they need.
These relationships generate revenue, advance investigator careers, and give your patients access to potentially breakthrough treatments. They also create conflicts of interest that require careful governance.
Delegate industry trial relationship management to your Clinical Trials Office and your VP of Research, with a clear conflict of interest governance framework that you and your board approve.
That framework should address: how investigators disclose financial relationships with industry sponsors, how potential conflicts are reviewed and managed, what restrictions apply to investigators who receive significant personal compensation from sponsors of trials they are running, and how your institution’s financial interests in a sponsor’s success are disclosed to trial participants.
The FDA’s guidance on financial disclosure by clinical investigators defines the federal baseline requirements. Your institution’s conflict of interest policies should meet or exceed these requirements, and your conflict of interest committee should operate independently of the research revenue considerations that might otherwise bias its decisions.
Delegating Research Safety Reporting
Adverse event reporting in clinical trials is a regulated, time-critical function. Federal regulations require prompt reporting of unanticipated problems involving risks to participants to the IRB, and serious adverse events to the sponsor and, in some cases, to the FDA.
This reporting function should be fully delegated to your Clinical Trials Office and your IRB, with a clear protocol that specifies reporting timelines, escalation criteria, and documentation requirements. Investigators have primary responsibility for identifying and reporting adverse events. The Clinical Trials Office has administrative responsibility for ensuring reports are submitted on time and to the right parties.
Your role in adverse event reporting is escalation-driven, not routine. You should receive a periodic summary (monthly or quarterly) of serious adverse event activity across your clinical trials portfolio. You should be notified immediately when an adverse event triggers a clinical hold, a sponsor termination of a trial, or a regulatory inquiry.
Build the escalation protocol explicitly and test it. Many institutions discover gaps in their adverse event escalation protocols only when a serious event has already occurred. Conduct periodic tabletop exercises with your research leadership team to identify gaps before they become patient safety failures.
Research Integrity and Misconduct Investigations
Research misconduct, including fabrication, falsification, and plagiarism, is a serious institutional risk that requires clear delegation of investigative authority and a defined process that is consistent with federal requirements under 42 CFR Part 93.
Delegate research misconduct investigations to your Research Integrity Officer (RIO) or equivalent, who typically reports to the VP of Research or directly to the CEO for matters that implicate senior investigators. The RIO is responsible for managing the inquiry and investigation process, ensuring due process for accused researchers, and reporting findings to the relevant funding agencies.
Your role in research misconduct matters is governance-level: ensuring the RIO function exists and is adequately independent, approving institutional responses to federal oversight bodies, and making final decisions about personnel actions that result from substantiated misconduct findings.
Do not involve yourself in the investigation process. CEO involvement in a research misconduct investigation can compromise the due process protections that both the accused researcher and the institution need. Maintain the institutional process, let the RIO execute it, and engage at the decision point where institutional authority is required.
For how research credentialing and the investigator relationship connect to your broader physician governance model, the healthcare physician delegation article covers the authority structures that keep credentialing decisions grounded in clinical standards rather than commercial considerations.
Building a Research Culture That Supports Delegation
The most effective long-term delegation model for healthcare research is cultural: building an organization where investigators, clinical research coordinators, compliance staff, and administrative leaders all share a genuine commitment to research integrity, participant safety, and regulatory compliance.
This culture starts with the CEO. Your visible commitment to research integrity, even when it is commercially inconvenient, sets the institutional tone more effectively than any policy or compliance training program.
Specific behaviors that shape research culture: attend the annual research awards event and recognize investigators who demonstrate exceptional participant protection, not just high grant revenue. When a compliance finding results in a trial being put on hold, respond with an emphasis on participant safety rather than the financial impact of the hold. When a senior investigator is found to have violated conflict of interest policies, apply the same consequences you would apply to any other employee, regardless of their grant revenue.
These choices are visible to your research community. They tell investigators, coordinators, and staff whether the institution’s commitment to research integrity is genuine or performative.
Tracking Research Enterprise Performance
Research enterprise performance requires a distinct measurement framework. You cannot apply standard operational KPIs to a function where the most important outcomes, scientific discoveries and patient benefit, emerge over years or decades.
The metrics you should receive from your VP of Research and track at the CEO level:
Research funding metrics: Total grant revenue, funding success rates by institute and funding agency, renewal rates for major grants, and industry trial revenue trends.
Research compliance metrics: IRB approval timeliness, adverse event reporting compliance rates, conflict of interest disclosure completion rates, and outcomes of compliance audits.
Research quality metrics: Protocol deviation rates, data quality audit outcomes, and trial completion rates versus enrollment projections.
Research output metrics: Publications, patents, and technology transfer activity generated by your research portfolio.
Research participant metrics: Enrollment by demographic group (with attention to diversity and inclusion in clinical research), participant retention rates, and participant satisfaction where measured.
Receive this dashboard quarterly. Use it to hold your VP of Research and Clinical Trials Office Director accountable for the health of the research enterprise. The metrics will surface problems long before they become crises, which is the entire point of a performance management system.
Healthcare CEOs who build strong research delegation models create institutions that attract top investigators, win competitive funding, and contribute meaningfully to scientific progress while protecting the patients who make that progress possible. That combination, scientific excellence and participant protection, is the standard the best research institutions set and maintain.
Related Reading
For further context, explore How Healthcare CEOs Delegate Board Governance and How Healthcare CEOs Delegate Clinical Quality and Outcomes.